Literature DB >> 8894176

Effects of cantharidin on force of contraction and phosphatase activity in nonfailing and failing human hearts.

B Linck1, P Boknik, J Knapp, F U Müller, J Neumann, W Schmitz, U Vahlensieck.   

Abstract

1. The effect of the phosphatase inhibitor, cantharidin (3-300 microM) on force of contraction was studied in isolated electrically driven right ventricular trabeculae carneae from human myocardium. 2. The positive inotropic effect of cantharidin started at a concentration of 100 microM with a positive inotropic effect to 199% and to 276% of the predrug value in nonfailing and failing human hearts, respectively. 3. Under basal conditions the contraction time parameters were prolonged in human heart failure vs. nonfailing preparations. However, the positive inotropic effect of cantharidin did not affect contraction time parameters. Thus, time to peak tension, time of relaxation and total contraction time were not shortened by cantharidin in nonfailing and failing preparations. 4. The phosphatase activity was unchanged in preparations from failing hearts compared to nonfailing hearts. 5. Cantharidin inhibited phosphatase activity in a concentration-dependent manner. The IC50 value of cantharidin was about 3 microM in both nonfailing and failing human myocardium. 6. The positive inotropic effect of cantharidin was similar in nonfailing and failing human hearts, accompanied by a similar inhibitory effect of cantharidin on the phosphatase activity. The positive inotropic effect of cantharidin in failing hearts was as strong as the effect of isoprenaline in nonfailing hearts. 7. It is concluded that the treatment with a phosphatase inhibitor may offer a new positive inotropic modality for the treatment of human heart failure.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8894176      PMCID: PMC1915706          DOI: 10.1111/j.1476-5381.1996.tb15706.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  20 in total

1.  Increase in myocardial Gi-proteins in heart failure.

Authors:  J Neumann; W Schmitz; H Scholz; L von Meyerinck; V Döring; P Kalmar
Journal:  Lancet       Date:  1988-10-22       Impact factor: 79.321

2.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

3.  Calcium-independent activation of contractile apparatus in smooth muscle by calyculin-A.

Authors:  H Ishihara; H Ozaki; K Sato; M Hori; H Karaki; S Watabe; Y Kato; N Fusetani; K Hashimoto; D Uemura
Journal:  J Pharmacol Exp Ther       Date:  1989-07       Impact factor: 4.030

4.  Cardiac contractile protein phosphatases. Purification of two enzyme forms and their characterization with subunit-specific antibodies.

Authors:  M C Mumby; K L Russell; L J Garrard; D D Green
Journal:  J Biol Chem       Date:  1987-05-05       Impact factor: 5.157

5.  beta-Adrenergic stimulation of phospholamban phosphorylation and Ca2+-ATPase activity in guinea pig ventricles.

Authors:  J P Lindemann; L R Jones; D R Hathaway; B G Henry; A M Watanabe
Journal:  J Biol Chem       Date:  1983-01-10       Impact factor: 5.157

6.  Autonomic regulation of type 1 protein phosphatase in cardiac muscle.

Authors:  Z Ahmad; F J Green; H S Subuhi; A M Watanabe
Journal:  J Biol Chem       Date:  1989-03-05       Impact factor: 5.157

7.  On the cardiac contractile, biochemical and electrophysiological effects of cantharidin, a phosphatase inhibitor.

Authors:  J Neumann; S Herzig; P Boknik; M Apel; G Kaspareit; W Schmitz; H Scholz; M Tepel; N Zimmermann
Journal:  J Pharmacol Exp Ther       Date:  1995-07       Impact factor: 4.030

8.  Abnormal intracellular calcium handling in myocardium from patients with end-stage heart failure.

Authors:  J K Gwathmey; L Copelas; R MacKinnon; F J Schoen; M D Feldman; W Grossman; J P Morgan
Journal:  Circ Res       Date:  1987-07       Impact factor: 17.367

9.  Increase of the 40,000-mol wt pertussis toxin substrate (G protein) in the failing human heart.

Authors:  A M Feldman; A E Cates; W B Veazey; R E Hershberger; M R Bristow; K L Baughman; W A Baumgartner; C Van Dop
Journal:  J Clin Invest       Date:  1988-07       Impact factor: 14.808

10.  Deficient production of cyclic AMP: pharmacologic evidence of an important cause of contractile dysfunction in patients with end-stage heart failure.

Authors:  M D Feldman; L Copelas; J K Gwathmey; P Phillips; S E Warren; F J Schoen; W Grossman; J P Morgan
Journal:  Circulation       Date:  1987-02       Impact factor: 29.690

View more
  7 in total

1.  Inhibition of mouse neuromuscular transmission and contractile function by okadaic acid and cantharidin.

Authors:  S J Hong
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

2.  Constitutive phosphorylation of inhibitor-1 at Ser67 and Thr75 depresses calcium cycling in cardiomyocytes and leads to remodeling upon aging.

Authors:  Stela Florea; Ahmad Anjak; Wen-Feng Cai; Jiang Qian; Elizabeth Vafiadaki; Sarah Figueria; Kobra Haghighi; Jack Rubinstein; John Lorenz; Evangelia G Kranias
Journal:  Basic Res Cardiol       Date:  2012-07-10       Impact factor: 17.165

3.  Molecular mechanisms underlying cardiac protein phosphatase 2A regulation in heart.

Authors:  Sean T DeGrande; Sean C Little; Derek J Nixon; Patrick Wright; Jedidiah Snyder; Wen Dun; Nathaniel Murphy; Ahmet Kilic; Robert Higgins; Philip F Binkley; Penelope A Boyden; Cynthia A Carnes; Mark E Anderson; Thomas J Hund; Peter J Mohler
Journal:  J Biol Chem       Date:  2012-11-30       Impact factor: 5.157

4.  Norcantharidin toxicity profile: an in vivo murine study.

Authors:  Gabriel Martínez-Razo; María Lilia Domínguez-López; José M de la Rosa; Diego A Fabila-Bustos; Elba Reyes-Maldonado; Eliezer Conde-Vázquez; Armando Vega-López
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-10-03       Impact factor: 3.195

Review 5.  Role of protein phosphatase-1 inhibitor-1 in cardiac physiology and pathophysiology.

Authors:  Persoulla Nicolaou; Roger J Hajjar; Evangelia G Kranias
Journal:  J Mol Cell Cardiol       Date:  2009-05-27       Impact factor: 5.000

6.  Role of PP1 in the regulation of Ca cycling in cardiac physiology and pathophysiology.

Authors:  Persoulla Nicolaou; Evangelia G Kranias
Journal:  Front Biosci (Landmark Ed)       Date:  2009-01-01

7.  Multiparametric Mechanistic Profiling of Inotropic Drugs in Adult Human Primary Cardiomyocytes.

Authors:  Najah Abi-Gerges; Tim Indersmitten; Ky Truong; William Nguyen; Phachareeya Ratchada; Nathalie Nguyen; Guy Page; Paul E Miller; Andre Ghetti
Journal:  Sci Rep       Date:  2020-05-06       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.